Nutlin-3

For research use only.

Catalog No.S1061

65 publications

Nutlin-3 Chemical Structure

CAS No. 890090-75-2

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 647 In stock
USD 970 In stock
USD 1617 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Nutlin-3 has been cited by 65 publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SMMC-7721  M2TkUmZ2dmO2aX;uJGF{e2G7 M2DSdlExKM7:TR?= NXKydI9mOzZiaB?= MlzXSG1UVw>? M2fadYRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ NE[wOIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK4OlMyOid-MkSyPFY{OTJ:L3G+
HuH-7 M{jFWmFxd3C2b4Ppd{BCe3OjeR?= MU[yNEDPxE1? M3rQWFQ5KGh? MWDEUXNQ M{LHVolv\HWlZYOgZZBweHSxc3nz NIjidVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK4OlMyOid-MkSyPFY{OTJ:L3G+
SMMC-7721  M2r5dGFxd3C2b4Ppd{BCe3OjeR?= Moj2NlAh|ryP MmTaOFghcA>? Ml;iSG1UVw>? M1LIeIlv\HWlZYOgZZBweHSxc3nz NHX1ZXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK4OlMyOid-MkSyPFY{OTJ:L3G+
HuH-7 M2f2SWNmdGxiVnnhZoltcXS7IFHzd4F6 M3jOZlEvOjVvMkCg{txO MoHkNlQwPDhxN{KgbC=> NFK4T3VFVVOR NGLUbHVqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NkOxNkc,OjR{OE[zNVI9N2F-
SMMC-7721  NHTufoVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUfvVXBKOS5{NT2yNEDPxE1? NIq4e20zPC92OD:3NkBp NIi4R2RFVVOR M4TnTolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NkOxNkc,OjR{OE[zNVI9N2F-
RKO NF6yTJNHfW6ldHnvckBCe3OjeR?= Ml:wNlAh|ryP NWPUOYdFOjRiaB?= MofjbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= NVWxXpN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlYxODdpPkK0N|Y3ODB5PD;hQi=>
U2OS  NVTs[3JRTnWwY4Tpc44hSXO|YYm= NYLKbJpCOjBizszN MnrRNlQhcA>? MYrpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= Mne2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|Nk[wNFcoRjJ2M{[2NFA4RC:jPh?=
RKO MmHySpVv[3Srb36gRZN{[Xl? NWrGeVNPOjBizszN MWeyOEBp NYDlS41bcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= NVvJfYNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlYxODdpPkK0N|Y3ODB5PD;hQi=>
U2OS  M4DJcGZ2dmO2aX;uJGF{e2G7 MknKNlAh|ryP NGjwfJEzPCCq MVHpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv NVr2S4w3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOlYxODdpPkK0N|Y3ODB5PD;hQi=>
MOLM NXz1ZZZDTnWwY4Tpc44hSXO|YYm= MXWxNEDPxE1? M37s[lI1KGh? MWX1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? NXPFSWlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|M2PjJpPkK0OFc{PTZ{PD;hQi=>
OCI MXXGeY5kfGmxbjDBd5NigQ>? M321[|ExKM7:TR?= MlfSNlQhcA>? NWr2VnpqfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u NWfaOIFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|M2PjJpPkK0OFc{PTZ{PD;hQi=>
BeWo MmfxRZBweHSxc3nzJGF{e2G7 Ml6yN|AhyrWP M2LQVVI1KGh? MlK2bY5kemWjc3XzJIFxd3C2b4Ppdy=> M{DVPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm4NVU1Lz5{NES5PFE2PDxxYU6=
BeWo NID4cJFHfW6ldHnvckBCe3OjeR?= MnjVN|AhyrWP NIqzZZAzPCCq M2TYZolv[3KnYYPld{BxPTNuIF3kcVItKHB{MTDhcoQhWHWvYTDheEB1cGVicILveIVqdiCuZY\lcC=> MnP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUixOVQoRjJ2NEm4NVU1RC:jPh?=
MOML13 NV\FblNmTnWwY4Tpc44hSXO|YYm= MWOxNO69VQ>? M2XES|IwPCCq MoLybY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3OUe0PUc,OjR4NUm3OFk9N2F-
AML3 Mm\qSpVv[3Srb36gRZN{[Xl? NGjuTncyOM7:TR?= NULwZ3lEOi92IHi= MmjQbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= M324fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW5O|Q6Lz5{NE[1PVc1QTxxYU6=
AML2 MY\GeY5kfGmxbjDBd5NigQ>? NFHXdG8yOM7:TR?= MnnFNk81KGh? NIDYe3ZqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MnTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O|Q6RC:jPh?=
MOML13 MWDBdI9xfG:|aYOgRZN{[Xl? NH;EZVYzNzFyIN88US=> MoewNlQwPDhiaB?= M3Hr[Ilv\HWlZYOgZZBweHSxc3nz MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3OUe0PUc,OjR4NUm3OFk9N2F-
AML2 NHmzWIxCeG:ydH;zbZMhSXO|YYm= M3\MRVIwOTBizszN NFnSdXMzPC92ODDo NH;Nb5NqdmS3Y3XzJIFxd3C2b4Ppdy=> NFOzRnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1PVc1QSd-MkS2OVk4PDl:L3G+
U2OS  MYLGeY5kfGmxbjDBd5NigQ>? M4fuW|IxKM7:TR?= NGPsZm0zPCCq NELYelVqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4N{K1PUc,OjR6NkeyOVk9N2F-
Hep3B MmXvRZBweHSxc3nzJGF{e2G7 M{\vNIlv\HWlZYOgZZBweHSxc3nz NIrub2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
Huh-7 NIO2TGhCeG:ydH;zbZMhSXO|YYm= NXWw[FZScW6mdXPld{BieG:ydH;zbZM> NEn5bnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
SMMC7721 NY\XN2t3SXCxcITvd4l{KEG|c3H5 NWDSbWZicW6mdXPld{BieG:ydH;zbZM> Mnv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OES4NFkoRjJ2OEi0PFA6RC:jPh?=
HepG2 MVrBdI9xfG:|aYOgRZN{[Xl? MXrpcoR2[2W|IHHwc5B1d3Orcx?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NEiwPUc,OjR6OES4NFk9N2F-
Hep3B NHPveHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvPWWo4OiCq NWf2WFQ4TE2VTx?= MXTJR|UxRTJyLkG4JOKyKDFwOESg{txO NWrxWZBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
Huh-7 MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLlN5U1PzJiaB?= NF\LeXJFVVOR NF7PRpNKSzVyPUOzMlk3KMLzIEOuPUDPxE1? NX7Gb2VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
SMMC7721/Ac NFrKSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjGb5JuPzJiaB?= NXnrTVJMTE2VTx?= NEnKTYdKSzVyPUW1MlIyKMLzIEWuNFMh|ryP NEH6bm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
SMMC7721 NFm0ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjSW2NYPzJiaB?= MmfRSG1UVw>? M{HET2lEPTB;M{GuNlghyrFiND6yJO69VQ>? NIPkPJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
HepG2/As MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;vUZYxPzJiaB?= M1[3R2ROW09? M{fiU2lEPTB;NkiuNVMhyrFiOT62JO69VQ>? NVn2OpcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
HepG2 M3\qN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nOe|czKGh? M4XnSmROW09? MVjJR|UxRTN3Lki2JOKyKDJwOTFOwG0> M4rrT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
MOLM-13 NV;aVoMzTnWwY4Tpc44hSXO|YYm= NHnyTmI3yqEQvF2= NUXjNmZzPiCq NHXmS|VFVVOR MYflcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly NVTrd5NRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFUxQDJpPkK0PFg2ODh{PD;hQi=>
MOLM-13 M3LpOWZ2dmO2aX;uJGF{e2G7 NXiwcoxkPsLizszN MmDnNE05KGh? MVfEUXNQ Mn7KbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ NXniToxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFUxQDJpPkK0PFg2ODh{PD;hQi=>
115 MmPaSpVv[3Srb36gRZN{[Xl? M2DUS|Uh|ryP NH;NNHk1QCCq MnLjSG1UVw>? M3zPcolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NHK2WHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
A498 Mmn1SpVv[3Srb36gRZN{[Xl? NUHPWo5EPSEQvF2= MYW0PEBp NEPMe2pFVVOR NY\vOHplcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NXvleG1nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
Caki-2 NFLLeIlHfW6ldHnvckBCe3OjeR?= MX[1JO69VQ>? NY[5VnRwPDhiaB?= NFTpSpNFVVOR MUPpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi M3jrU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
ACHN NXjMSJVyTnWwY4Tpc44hSXO|YYm= MYi1JO69VQ>? MXO0PEBp MnG4SG1UVw>? NUHCPVdJcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> M2Lyc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
115 NYHzV2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3idoo4PSEQvF2= Mn7pOFghcA>? NI\XZ25FVVOR NEjse5hqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> M2rGTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
A498 NWr4Nng5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW1JO69VQ>? NYnlO2pOPDhiaB?= MoTqSG1UVw>? NV\TWW82cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
Caki-2 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrqOUDPxE1? NWHvfmV7PDhiaB?= MYPEUXNQ MV\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M1zKS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
ACHN NXTkbotHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LUb|Uh|ryP MYm0PEBp M1m2SGROW09? M3fLOIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MlruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
115 MXXGeY5kfGmxbjDBd5NigQ>? MVewMlUwOS93IN88US=> NE\GbIU1QCCq NGG1OJlFVVOR MljvcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M1LnU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
A498 MXHGeY5kfGmxbjDBd5NigQ>? NVnwflh2OC53L{GvOUDPxE1? M3S3Z|Q5KGh? MmrsSG1UVw>? M{LZS4xm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NI\1bHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
Caki-2 M{HVXWZ2dmO2aX;uJGF{e2G7 MYGwMlUwOS93IN88US=> M4fL[VQ5KGh? NWjvOlZPTE2VTx?= MoDGcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M4G1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
ACHN NIHITmVHfW6ldHnvckBCe3OjeR?= MnfrNE42NzFxNTFOwG0> NWfRPXJxPDhiaB?= NY\V[lhHTE2VTx?= NV;ibI1sdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= MojJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
117 NX7CTGgxS2WubDDWbYFjcWyrdImgRZN{[Xl? MXGwMlUuOTBizszN MYKwMVYh\A>? M4nyWmROW09? M3j3XYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXPPVFRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
115 Mn7DR4VtdCCYaXHibYxqfHliQYPzZZk> M3PnSFAvPS1zMDFOwG0> NHHZSJExNTZiZB?= NGPBR5ZFVVOR NXKwb3JGcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
A498 MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFWyTXIxNjVvMUCg{txO NHrZXZcxNTZiZB?= NVO2NpBQTE2VTx?= MWfpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3;lflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
Caki-2 NYDQ[ldPS2WubDDWbYFjcWyrdImgRZN{[Xl? M4\YeFAvPS1zMDFOwG0> M3KyR|AuPiCm NYXDXmwxTE2VTx?= MkflbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4[1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
ACHN Mmi2R4VtdCCYaXHibYxqfHliQYPzZZk> NHX1T|YxNjVvMUCg{txO Mk\INE03KGR? NYLaNnBXTE2VTx?= Mn[5bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
MCF7  M2XJXGZ2dmO2aX;uJGF{e2G7 MYSyMlUhyrWP MUe0PEBp NEW1TWlFVVOR NWXSUnd3\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? NUTQWHlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFU6ODJpPkK1NFg2QTB{PD;hQi=>
MCF7  NVG5TFg1S2WubDDWbYFjcWyrdImgRZN{[Xl? M1nGPFIvPSEEtV2= NGH1UnY2KGR? M4LMN2ROW09? MlTnd4Vve2m2aYrld{BOS0Z5IITvJHBCWlBiaX7obYJqfGmxbh?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB6NUmwNkc,OjVyOEW5NFI9N2F-
RAW 264.7 NUjldnNwTnWwY4Tpc44hSXO|YYm= MkHzNVDDqM7:TR?= NVjId4xSOzBibXnu NUXMcWZ3cW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh M2XFZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOVQ4Lz5{NUG3NlU1PzxxYU6=
RAW 264.7 M3ry[GZ2dmO2aX;uJGF{e2G7 MXSxNOKh|ryP M3TzTVMxKG2rbh?= NGHyZZRz\WS3Y3XzJJRp\SCOUGOtZZVodWWwdHXkJJRp\SCQRj5OvmIhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5 MnjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzN{K1OFcoRjJ3MUeyOVQ4RC:jPh?=
RAW 264.7 M{L6NWZ2dmO2aX;uJGF{e2G7 NILqTlUyOMLizszN MWizNEBucW5? M3jETJBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> NFnFc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlU1Pyd-MkWxO|I2PDd:L3G+
SUM102PT NXvVfVFnTnWwY4Tpc44hSXO|YYm= NVT0SpJjOTEEoN88US=> MXuyOEBp MWTEUXNQ NIDBNVJqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MmjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O|I6RC:jPh?=
SK-BR-7 MmfHSpVv[3Srb36gRZN{[Xl? MnHlNVDDqM7:TR?= MV6yOEBp NETmXZVFVVOR NWDhT5pWcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NXy3ZVRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOVc4OjlpPkK1NlU4PzJ7PD;hQi=>
MCF-10CA1a NHPENmlHfW6ldHnvckBCe3OjeR?= NWm4enFHOTEEoN88US=> NHfqdYEzPCCq NUj3UYc1TE2VTx?= NFfGc4FqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M4jWe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkW3O|I6Lz5{NUK1O|czQTxxYU6=
MCF-10CA1a NHj0PJBHfW6ldHnvckBCe3OjeR?= MXGxNOKh|ryP MmH6NlQhcA>? M{jJOmROW09? M1:yc4Rm[3KnYYPld{B1cGViVFfGMe6zOy2rbnT1Z4VlKG2UTlGgcIV3\Wy|IH;mUW1ROi{EoF3NVFktKGGwZNMgbY51\We{aX9CpO6zyqB| M32xOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkW3O|I6Lz5{NUK1O|czQTxxYU6=
MCF-10A1  MWLGeY5kfGmxbjDBd5NigQ>? NV;lfHd2OTEEoN88US=> M2nkV|I1NzR6IHi= MVPEUXNQ NWfPd5QycW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
MCF-10CA1a M2fHOGZ2dmO2aX;uJGF{e2G7 NULVTZI6OTEEoN88US=> MYK0PEBp M{DSNmROW09? MYDpcohq[mm2czDiZZNidCCrbo\hd4lwdiCjbnSgdoVlfWOnZDDUS2Yu|rJ|LXnu[JVk\WRiaX72ZZNqd25idH:gZoF{[WxibHX2[Yx{ MmOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O|I6RC:jPh?=
HCT116  NHOyfoNHfW6ldHnvckBCe3OjeR?= NHO2NGEyOCEEtV2= NFHxbJgzPCCq MWnjZZV{\XNiYTDwOVMu\GWyZX7k[Y51KHSndILhdIxwcWRiR{GtZZJz\XO2IHnuJIRqeGyxaXSgTGNVOTF4IHPsc45meyCGMzDhcoQhTDh? NUmxUFFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFAxPTVpPkK1N|gxODV3PD;hQi=>
A2780 MWfGeY5kfGmxbjDBd5NigQ>? M4jPN|ExyqEQvF2= MkfxNlFpyqB? NEHC[5RFVVOR MYXk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= NHXmUIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOlU1QCd-MkW0NlY2PDh:L3G+
NCI-H23 MnrESpVv[3Srb36gRZN{[Xl? MWOxNOKh|ryP M3PIdFIycMLi NVe5N|NWTE2VTx?= M4XyZoRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NkW0PEc,OjV2Mk[1OFg9N2F-
A2780 NH\hPJJHfW6ldHnvckBCe3OjeR?= MofDNVDDqM7:TR?= NFP2TlAzOWkEoB?= NV3SOHB1TE2VTx?= M1jnNYlv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> M2rHbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK2OVQ5Lz5{NUSyOlU1QDxxYU6=
NCI-H23 M2fyd2Z2dmO2aX;uJGF{e2G7 MlrVNVDDqM7:TR?= Mli4NlFpyqB? NFLUe2dFVVOR NGiyeYtqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ NEPqXWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOlU1QCd-MkW0NlY2PDh:L3G+
OVCAR10 MYDGeY5kfGmxbjDBd5NigQ>? MVGxNOKh|ryP NXmxWYhQOjGqwrC= M4rW[WROW09? Mn24bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> M3z2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK2OVQ5Lz5{NUSyOlU1QDxxYU6=
MCF-7 M{\CNWZ2dmO2aX;uJGF{e2G7 MmjuNVDDqM7:TR?= NG\ySmkxNTJ2IHi= NFrt[|RqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEKzO|MoRjJ3NEiyN|c{RC:jPh?=
SMMC-7721 MUnGeY5kfGmxbjDBd5NigQ>? M17zflExKM7:TR?= NUDweJJROzZiaB?= NYrsXohETE2VTx?= MlT1Z4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV2NEO2NUc,OjV3NESzOlE9N2F-
SMMC-7721 NUnUTIlGTnWwY4Tpc44hSXO|YYm= MVuxNEDPxE1? NUfyZ2Z{PDhiaB?= NXjoSZh{TE2VTx?= Mm\ubY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> Mk\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NESzOlEoRjJ3NUS0N|YyRC:jPh?=
SMMC-7721 M4r0eWZ2dmO2aX;uJGF{e2G7 M1TnbVExKM7:TR?= NYHpfJNYPDhiaB?= M1jje2ROW09? NGrDNmJqdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKh MlryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NESzOlEoRjJ3NUS0N|YyRC:jPh?=
SMMC-7721 NVTQNmI{TnWwY4Tpc44hSXO|YYm= NUjQVXd3OTBizszN MWq0PEBp M2GyPGROW09? MmTGZ4F2e2W|IFTORUBFW0JiZHHtZYdm NFXjZZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0OFM3OSd-MkW1OFQ{PjF:L3G+
DU4475  NYqxcIU5TnWwY4Tpc44hSXO|YYm= MnzxOU8yOC9{MDFOwG0> MnTINlTDqGh? M3HBRoRwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> NUf0T5NsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OFcyPzRpPkK1OVQ4OTd2PD;hQi=>
MCF-7  MX3GeY5kfGmxbjDBd5NigQ>? MUexNOKh|ryP NGHw[HRFVVOR NEjo[2lqdmirYnn0d{BkgWOuaX6gSFEh[W6mIFTpZ4VzyqB? M4f0ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CyO|A{Lz5{NUewNlcxOzxxYU6=
C2C12 NIHUXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLkOXMyOMLizszNxsA> NYnTV3VZOjRxNEivO|IhcA>? NXj3TWdvTE2VTx?= M4LST4lvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? NV\Bbm9vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O|E4QTRpPkK1PFcyPzl2PD;hQi=>
L6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNOKh|ryPwrC= M3L2eVI1NzR6L{eyJIg> NX\3XFJbTE2VTx?= NYXJ[phmcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5MUe5OEc,OjV6N{G3PVQ9N2F-
CRL-5908 NHvrb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzwPGUzPCCq MXLJR|UxRTN6LkexJOKyKDJwNEOg{txO MmTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkWyN|AoRjJ4MUK1NlMxRC:jPh?=
A549-920 M174fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmyOEBp MmnaTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? NI\MVIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI{OCd-Mk[xNlUzOzB:L3G+
A549-NTC M3ju[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HQcVI1KGh? M4jQfmlEPTB;MUmuOFIhyrFiMT65OkDPxE1? NUnjdmtPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzOzBpPkK2NVI2OjNyPD;hQi=>
A549 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGyOEBp NVfPZXNVUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= NGjMNnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI{OCd-Mk[xNlUzOzB:L3G+
C666-1 NFfT[2ZCeG:ydH;zbZMhSXO|YYm= NGDhR|EyOCEEtV2= NYjGdZlNPDhxN{KgbC=> NVztOYZjTE2VTx?= MlnDd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3MkW3OUc,OjZ{NUK1O|U9N2F-
C666-1  M4i2dmZ2dmO2aX;uJGF{e2G7 MkSzNVAhyrWP NVTjZWNWOjRiaB?= MXPEUXNQ NFrDWlZi[3SrdnH0[ZMhfGinIIC1N{Bx[XSqd3H5MEB2eHKnZ4XsZZRqdmdicEWzMEBxOjFiYX7kJG1ldTJ? NV;XVpBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
C666-1 M{LJNGNmdGxiVnnhZoltcXS7IFHzd4F6 MVSxNEDDvU1? NV3QTIJ7PDhiaB?= MX\EUXNQ MWHz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzD0bIUh[3m2b4TvfIlkKGWoZnXjeEBw\iClaYPwcIF1cW5? NXzTdVFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
C666-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu3cIFKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? NIji[ZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NlU4PSd-Mk[yOVI2PzV:L3G+
NP460 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ{Lki1xtEyNjF6IN88US=> MnnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O|UoRjJ4MkWyOVc2RC:jPh?=
NP69 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjlfHpEUUN3ME2zNU43QcLzMj61OEDPxE1? M{nZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkWyOVc2Lz5{NkK1NlU4PTxxYU6=
MCF7 M4rNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLIOeKh|ryP MmDSOFjDqGh? M2XodoJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? NGXsdmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NFU3PSd-Mk[zOVA2PjV:L3G+
HuH-7 M2\BXmZ2dmO2aX;uJGF{e2G7 NUHrS2hXOTBizszN MnT3N|YhcA>? M3zWemROW09? M2[3XoRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ NYXablZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
AT2 NHPVbVNHfW6ldHnvckBCe3OjeR?= MVe1M|ExKM7:TR?= NFLKW|lt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MEKwN{c,OjR{NECyNFM9N2F-
REH NFzRN3lHfW6ldHnvckBCe3OjeR?= MWO1M|ExKM7:TR?= MlrMcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? M2\6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSwNlA{Lz5{NEK0NFIxOzxxYU6=
UoCB6 M1TqPGZ2dmO2aX;uJGF{e2G7 MVS1M|ExKM7:TR?= NVXOVVB7dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= NXPFT|FRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB|PD;hQi=>
AT2 MlviR4VtdCCYaXHibYxqfHliQYPzZZk> NWLkdIVoOC1{NTFOwG0> NF;yWnVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWTqcll3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB|PD;hQi=>
REH NX\4bJRUS2WubDDWbYFjcWyrdImgRZN{[Xl? M1jTV|AuOjVizszN MUfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MmTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NECyNFMoRjJ2MkSwNlA{RC:jPh?=
UoCB6 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MU[wMVI2KM7:TR?= NUnONHJDcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MnWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NECyNFMoRjJ2MkSwNlA{RC:jPh?=
A2780 NVnhT3lHTnWwY4Tpc44hSXO|YYm= NFG3TJM2NzFyL{KwJO69VQ>? NIKx[4gzPCCq MmXZeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NHHBWWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOlE1Pyd-MkSxN|YyPDd:L3G+
H460 NGDMPHZHfW6ldHnvckBCe3OjeR?= MVe1M|ExNzJyIN88US=> M{LM[VI1KGh? MUD1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? M{jnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
Lovo  NVKxWXdETnWwY4Tpc44hSXO|YYm= MXy1M|ExNzJyIN88US=> MkHtNlQhcA>? M2LiOpVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NYjleHJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN|YyPDdpPkK0NVM3OTR5PD;hQi=>
A2780 MW\BdI9xfG:|aYOgRZN{[Xl? NXLjcJJ4PS9zMD:yNEDPxE1? MV2yOEBp NIXETWlmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? NFjrWXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOlE1Pyd-MkSxN|YyPDd:L3G+
H460 MnPMRZBweHSxc3nzJGF{e2G7 NYPqUZlZPS9zMD:yNEDPxE1? MoPwNlQhcA>? M122bYVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|NkG0O{c,OjRzM{[xOFc9N2F-
Lovo  MWPBdI9xfG:|aYOgRZN{[Xl? NHLVXXo2NzFyL{KwJO69VQ>? M{L3VlI1KGh? NHW2OYZmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? M2e2V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
U87MG NUjWTm9FTnWwY4Tpc44h[XO|YYm= MWGxNEBucW6| NX\nWlFSSmmwZHnu[{Bi\m[rbnn0fUB1dyCPRF2yJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVUSPMj;wOVMheHKxdHXpckBqdnSncnHjeIlwdiCjZoTldkAyOCCvaX7zJIJ6KHG3YX70bZRifGm4ZTDzZY5lf2mlaDDpcY12dm9iYYPzZZktKEmFNUCgQUAxNjFyNEWg{txONg>? NWHRVW06RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOVA4QDJpPkK3NFUxPzh{PD;hQi=>
U87MG MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NGjh[|g1QCCqcoO= NGHHc5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKHB3MzDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxKD1iNj61JO69VS5? NE\pdII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C1NFc5Oid-MkewOVA4QDJ:L3G+
U343MG M1TycWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MlyyOFghcHK| MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV|NEPNS{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBxPTNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF{Lk[g{txONg>? M1;kO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEWwO|gzLz5{N{C1NFc5OjxxYU6=
SW620 MYHDfZRwfG:6aXPpeJkh[XO|YYm= NFT1cXc4OiCqcoO= NIi4SphEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzZ{MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5|ODFOwG0v NWrEd2FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTlzM{O0M{c,S2iHTVLMQE9iRg>?
A549 MVXDfZRwfG:6aXPpeJkh[XO|YYm= NFzoV3A4OiCqcoO= MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCwMlQyKM7:TT6= MkHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVkyOzN2Lze+R4hGVUKOPD;hQi=>
SJSA1 NI\CNldEgXSxdH;4bYNqfHliYYPzZZk> MkjkO|IhcHK| NVvXfplRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0qVQUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDFwOEGg{txONg>? NGHHcXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,
HCT116 MnPUR5l1d3SxeHnjbZR6KGG|c3H5 NYDmUmlUPzJiaILz NXjIRppDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB2Lk[zJO69VS5? Ml7UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVkyOzN2Lze+R4hGVUKOPD;hQi=>
PC3 NGTJdFNEgXSxdH;4bYNqfHliYYPzZZk> MWe3NkBpenN? NEDScmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvOzdizszNMi=> NG\vbmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MDM2 / p53 / ALKBH2 / p21 / PUMA; 

PubMed: 23258843     


CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting.

RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; 

PubMed: 28507282     


(A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.

23258843 28507282
Immunofluorescence
Lamin A / Lamin C / p16 / H3K9me3; 

PubMed: 30728349     


c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. 

Merlin / cyclin D1 / p53 / MDM2; 

PubMed: 30274821     


The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm.

p53; 

PubMed: 24286312     


The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).

30728349 30274821 24286312
Growth inhibition assay
Cell viability; 

PubMed: 29286113     


Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.

29286113
In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

- Collapse

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

- Collapse
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3|Nutlin-3 ic50|Nutlin-3 price|Nutlin-3 cost|Nutlin-3 solubility dmso|Nutlin-3 purchase|Nutlin-3 manufacturer|Nutlin-3 research buy|Nutlin-3 order|Nutlin-3 mouse|Nutlin-3 chemical structure|Nutlin-3 mw|Nutlin-3 molecular weight|Nutlin-3 datasheet|Nutlin-3 supplier|Nutlin-3 in vitro|Nutlin-3 cell line|Nutlin-3 concentration|Nutlin-3 nmr|Nutlin-3 in vivo|Nutlin-3 clinical trial|Nutlin-3 inhibitor|Nutlin-3 Apoptosis inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID